Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC
26 Sep 2024
Dr Rosell presents at the Future Horizons in Lung Cancer meeting about immunotherapies.
Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC
ESMO 2024: Latest in EGFR mutated NSCLC
Biomarkers, predictive and prognostic factors of resistance to immunotherapy
Uncommon genetic aberrations NTRK, RET, NRG
ASCO 2024: Lung cancer highlights
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Updates on lung cancer from WCLC and ESMO 2023
OncoAlert round up July 28th to August 3rd, 2023
Four chemo cycles given with durvalumab and tremelimumab optimise response and tumour shrinkage in patients with mNSCLC